E
Elnaz Naseri
Researcher at Harvard University
Publications - 3
Citations - 318
Elnaz Naseri is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Regulation of gene expression. The author has an hindex of 3, co-authored 3 publications receiving 297 citations.
Papers
More filters
Journal ArticleDOI
PGC-1α regulates a HIF2α-dependent switch in skeletal muscle fiber types
Kyle A. Rasbach,Rana K. Gupta,Jorge L. Ruas,Jun Wu,Elnaz Naseri,Jennifer L. Estall,Bruce M. Spiegelman +6 more
TL;DR: A qPCR-based screen of all known transcriptional components to identify transcription factors that are quantitatively regulated by PGC-1α in cultured skeletal muscle cells identified hypoxia-inducible factor 2 α (HIF2α) as a major P GC-1 α target in skeletal muscle that is positively regulated by both exercise and β-adrenergic signaling.
Journal ArticleDOI
Synergy between PPARγ Ligands and Platinum-Based Drugs in Cancer
Geoffrey D. Girnun,Elnaz Naseri,Scott Bradley Vafai,Lishu Qu,Jeffrey D. Szwaya,Roderick T. Bronson,John A. Alberta,Bruce M. Spiegelman +7 more
TL;DR: There is a striking synergy between rosiglitazone and platinum-based drugs in several different cancers both in vitro and using transplantable and chemically induced “spontaneous” tumor models, which strongly suggest combining PPARγ agonists and platinum -based drugs for the treatment of certain human cancers.
Journal ArticleDOI
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
Geoffrey D. Girnun,Liang Chen,Jessica M. Silvaggi,Ronny Drapkin,Lucian R. Chirieac,Robert F. Padera,Rabi Upadhyay,Scott Bradley Vafai,Ralph Weissleder,Umar Mahmood,Elnaz Naseri,Stephanie Buckley,Danan Li,Jeremy Force,Kate McNamara,George D. Demetri,Bruce M. Spiegelman,Kwok-Kin Wong +17 more
TL;DR: Data show that the PPARγ ligand/carboplatin combination is a new therapy worthy of clinical investigation in lung cancers, including those cancers that show primary resistance to platinum therapy or acquired resistance to targeted therapy.